PF-592,379 is a drug developed by Pfizer which acts as a potent, selective and orally active agonist for the dopamine D3 receptor, which is under development as a potential medication for the treatment of female sexual dysfunction and male erectile dysfunction. Unlike some other less selective D3 agonists, a research study showed that PF-592,379 has little abuse potential in animal studies, and so was selected for further development and potentially human clinical trials.[1][2] Development has since been discontinued.[3]

PF-592,379
PF-592379 structure.png
Clinical data
Routes of
administration
Oral
Legal status
Legal status
  • Investigational (discontinued)
Identifiers
  • 5-[(2R,5S)-5-methyl-4-propylmorpholin-2-yl]pyridin-2-amine
CAS Number
PubChem CID
IUPHAR/BPS
ChemSpider
UNII
Chemical and physical data
FormulaC13H21N3O
Molar mass235.331 g·mol−1
3D model (JSmol)
  • CCCN([C@@H](C)CO1)C[C@H]1C2=CN=C(N)C=C2
  • InChI=1S/C13H21N3O/c1-3-6-16-8-12(17-9-10(16)2)11-4-5-13(14)15-7-11/h4-5,7,10,12H,3,6,8-9H2,1-2H3,(H2,14,15)/t10-,12-/m0/s1
  • Key:DFTCYTDJDXZFSK-JQWIXIFHSA-N

See alsoEdit

ReferencesEdit

  1. ^ Attkins N, Betts A, Hepworth D, Heatherington AC (November 2010). "Pharmacokinetics and elucidation of the rates and routes of N-glucuronidation of PF-592379, an oral dopamine 3 agonist in rat, dog, and human". Xenobiotica; the Fate of Foreign Compounds in Biological Systems. 40 (11): 730–42. doi:10.3109/00498254.2010.514961. PMID 20836725. S2CID 30288414.
  2. ^ Collins GT, Butler P, Wayman C, Ratcliffe S, Gupta P, Oberhofer G, Caine SB (June 2012). "Lack of abuse potential in a highly selective dopamine D3 agonist, PF-592,379, in drug self-administration and drug discrimination in rats". Behavioural Pharmacology. 23 (3): 280–91. doi:10.1097/FBP.0b013e3283536d21. PMC 3365486. PMID 22470105.
  3. ^ "Drug Profile: PF 592379". Adis Insight. Springer Nature Switzerland AG.